We are live on ! Find out more

Viking Therapeutics

VKTX

Market cap $3.48B

27.28 USD

+0.42

1.56%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

26.88

-0.40

1.47%

1 day

1.56%

5 days

11.8%

1 month

-16.32%

3 months

-17.61%

6 months

-12.51%

Year to date

-22.98%

1 year

-28.53%

5 years

344.3%

10 years

2,449.53%

About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Employees: 74

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 51.5%

Neutral 34.3%

Negative 14.1%

Zacks Investment Research

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?

Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?

Zacks Investment Research

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)

Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for injectable VK2735, and SUNRISE trials for oral VK2735, are key 2025–2027 catalysts; >20% weight loss with strong safety could drive approval. Recent maintenance study data showed up to 21.7% mean weight loss and excellent tolerability with less frequent dosing, but competition and limited data durability remain concerns.

Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)

Zacks Investment Research

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

Zacks Investment Research

VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress

Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.

VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress

24/7 Wall Street

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving.

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock

Viking Therapeutics' maintenance data met upside criteria but failed to excite the market, with shares dropping post-release and dilution ongoing. VKTX is clearly pursuing a standalone strategy, ramping OpEx and infrastructure despite formidable competition from Eli Lilly and Novo Nordisk. Viking's multi-modal maintenance strategy—injectable induction followed by oral or monthly maintenance—addresses injection fatigue but faces a race against advancing competitors.

Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock

Viking Therapeutics Q3 Earnings Call Highlights

Viking Therapeutics NASDAQ: VKTX reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of its lead candidate, VK2735.

Viking Therapeutics Q3 Earnings Call Highlights

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated -- -- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Completion -- -- Strong Quarter-End Cash Position of $960 Million -- Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, Oct. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

See News Rankings

Price charts implemented using Lightweight Charts™